| Literature DB >> 24558112 |
Elena Gimeno-Santos1, Anja Frei2, Claudia Steurer-Stey3, Jordi de Batlle4, Roberto A Rabinovich5, Yogini Raste6, Nicholas S Hopkinson6, Michael I Polkey6, Hans van Remoortel7, Thierry Troosters7, Karoly Kulich8, Niklas Karlsson9, Milo A Puhan10, Judith Garcia-Aymerich11.
Abstract
BACKGROUND: The relationship between physical activity, disease severity, health status and prognosis in patients with COPD has not been systematically assessed. Our aim was to identify and summarise studies assessing associations between physical activity and its determinants and/or outcomes in patients with COPD and to develop a conceptual model for physical activity in COPD.Entities:
Keywords: COPD Exacerbations; COPD epidemiology; Exercise
Mesh:
Year: 2014 PMID: 24558112 PMCID: PMC4112490 DOI: 10.1136/thoraxjnl-2013-204763
Source DB: PubMed Journal: Thorax ISSN: 0040-6376 Impact factor: 9.139
Figure 1Flow diagram of process of systematic literature search. *Details for reason for exclusion in online supplementary table S1.
Reference details, design and number of subjects of 86 studies reporting associations between physical activity and its determinants or outcomes in patients with COPD
| Reference | Study design | n | Reference | Study design | n | Reference | Study design | n |
|---|---|---|---|---|---|---|---|---|
| Altenburg WA, 2013S1 | Cross sectional | 155 | Garcia-Aymerich J, 2004S30 | Cross sectional | 346 | Pitta, F. 2009S59 | Cross-sectional | 80 |
| Beauchamp MK, 2012S2 | Cross sectional | 37 | Garcia-Aymerich J, 2006S31 | Cohort | 2386 | Pomidori, L. 2012S60 | Randomised non-controlled parallel study | 36 |
| Behnke M, 2005S3 | Non-randomised controlled study | 88 | Garcia-Aymerich J, 2008S32 | Cohort | 2226 | Probst, VS. 2011S61 | Randomised non-controlled parallel study | 40 |
| Bendstrup KE, 1997S4 | Randomised controlled trial | 32 | Garcia-Aymerich J, 2009S33 | Cross sectional | 341 | Roig, M. 2011S62 | Cohort | 101 |
| Benzo R, 2010S5 | Cohort | 597 | Garcia-Rio F, 2009S34 | Cross sectional | 110 | Sandland, CJ. 2008S63 | Randomised controlled trial | 20 |
| Berry M, 2006S6 | Cross sectional | 291 | Garcia-Rio F, 2012S35 | Cohort | 173 | Schou, L. 2013S64 | Randomised controlled trial | 44 |
| Berry M, 2010S7 | Randomised non-controlled parallel study | 176 | Goto Y, 2004S36 | Non-randomised controlled study | 30 | Sewell, L. 2005S65 | Randomised non-controlled parallel study | 180 |
| Bestall J, 1999S8 | Cross sectional | 100 | Hartman JE, 2013S37 | Cross sectional | 113 | Sewell, L. 2010S66 | Non-controlled study | 95 |
| Bon J, 2011S9 | Cross sectional | 190 | Hataji O, 2013S38 | Non-controlled study | 23 | Silva, DR. 2011S67 | Cross-sectional | 95 |
| Bossenbroek L, 2009S10 | Case–control | 62 | Inal-Ince D, 2005S39 | Cross sectional | 30 | Skumlien, S. 2006S68 | Cross-sectional | 110 |
| Bourbeau J, 2007S11 | Cohort | 421 | Jehn M, 2012S40 | Cross sectional | 107 | Skumlien, S. 2008S69 | Non-randomised non-controlled parallel study | 40 |
| Breyer MK, 2010S12 | Randomised controlled trial | 60 | Katajisto M, 2012S41 | Cross sectional | 719 | Takigawa, N. 2007S70 | Non-controlled study | 225 |
| Chao PW, 2011S13 | Cross sectional | 21 | Lahaije A, 2013S42 | Cross sectional | 57 | Troosters, T. 2010, Respir MedS71 | Cross-sectional | 70 |
| Chen Y, 2006S14 | Cohort | 145 | Lee H, 2011S43 | Cross sectional | 131 | Tsara, V. 2008S72 | Case-control | 133 |
| Coronado M, 2003S15 | Non-controlled study | 15 | Lemmens KMM, 2008S44 | Cross sectional | 278 | Van Gestel, AJ. 2012S73 | Cross-sectional | 154 |
| Dal Negro R, 2010S16 | Randomised controlled trial | 32 | Lore, V, 2006S45 | Cross sectional | 23 | Van Remoortel, H. 2013S74 | Cross-sectional | 59 |
| Dallas MI, 2009S17 | Non-controlled study | 45 | Mador MJ, 2011S46 | Non-controlled study | 24 | Vergeret, J. 1989S75 | Cohort | 243 |
| Daly C, 2011S18 | Non-controlled study | 8 | Miravitlles M, 2011S47 | Cohort | 346 | Waatevik, M. 2012S76 | Cross-sectional | 370 |
| de Blok BM, 2006S19 | Randomised controlled trial | 21 | Monteiro F, 2012S48 | Cross sectional | 74 | Wakabayashi, R. 2011S77 | Randomised controlled trial | 102 |
| Effing T, 2011S20 | Randomised controlled trial | 153 | Moy M, 2009S49 | Cross sectional | 17 | Wakabayashi, R. 2011S78 | Cross-sectional | 389 |
| Egan C, 2012S21 | Non-controlled study | 47 | Moy M, 2013S50 | Cohort | 169 | Walker, PP. 2008S79 | Non-controlled study | 23 |
| Eisner MD, 2008S22 | Cross-sectional | 1202 | Nguyen HQ, 2009S51 | Randomised controlled trial | 17 | Waschki, B. 2011S80 | Cohort | 169 |
| Eliason G, 2011S23 | Cross-sectional | 44 | Nguyen HQ, 2013S52 | Cross-sectional | 148 | Watz, H. 2008S81 | Cross-sectional | 170 |
| Esteban C, 2006S24 | Cohort | 611 | Nield M, 2005S53 | Non-controlled study | 48 | Watz, H. 2009S82 | Cross-sectional | 170 |
| Esteban C, 2010S25 | Cohort | 391 | Okubadejo AA, 1997S54 | Case–control | 42 | Watz, H. 2009S83 | Cross-sectional | 163 |
| Esteban C, 2011S26 | Cohort | 611 | Palop Cervera M, 2010S55 | Case–control | 125 | Weekes, CE. 2009S84 | Randomised controlled trial | 59 |
| Faager G, 2004S27 | Randomised controlled trial | 20 | Pitta F, 2006S56 | Cohort | 17 | Wewel, A. 2008S85 | Non-controlled study | 21 |
| Faulkner J, 2010S28 | Randomised controlled trial | 20 | Pitta F, 2006S57 | Cross sectional | 23 | Yeo, J. 2006S86 | Cross-sectional | 27 |
| Garcia-Aymerich J, 2003S29 | Cohort | 340 | Pitta F, 2008S58 | Cross sectional | 40 |
Quality of evidence for determinants and outcomes of physical activity in COPD, as identified in 86 studies
| Determinant | N studies | Direction established | Control for confounding | Directness | Consistency | Strength | Low precision | Other | Confidence rating |
|---|---|---|---|---|---|---|---|---|---|
| AgeS30 S33 S34 S57 S71 S81 | 6 | na | na | Yes | −11 | No | No | No | +++ (moderate) |
| Alcohol consumptionS30 S34 | 2 | −22 | −14 | Yes | −11 | No | −16 | No | + (very low) |
| Cultural groupS14 S59 S71 | 3 | −12 | na | −13 | −11 | No | No | No | + (very low) |
| Day of the weekS45 S49 S82 | 3 | −22 | −14 | Yes | −11 | No | No | No | + (very low) |
| EducationS30 S33 S34 | 3 | −22 | −14 | Yes | −11 | No | No | No | + (very low) |
| Marital statusS30 S33 | 2 | −22 | −14 | Yes | −11 | No | No | No | + (very low) |
| SexS30 S33 S34 S57 S68 S81 | 6 | na | na | Yes | −11 | No | No | No | +++ (moderate) |
| Smoking habitS30 S33 S34 | 3 | −22 | −14 | Yes | −11 | No | −16 | No | + (very low) |
| Socioeconomic statusS30 S33 | 2 | −22 | −15 | Yes | −11 | No | No | No | + (very low) |
| Working statusS30 S33 S34 | 3 | −22 | −14 | Yes | −11 | No | No | No | + (very low) |
| BODE indexS34 S49 S57 S81 S83 | 5 | −22 | −15 | Yes | −11 | No | No | No | + (very low) |
| Body mass indexS30 S34 S48 S57 S81 | 5 | −22 | −15 | Yes | −11 | No | No | No | + (very low) |
| CardiovascularS30 S81 | 2 | −22 | −15 | Yes | −11 | No | −16 | −17 | + (very low) |
| DyspnoeaS8 S41 S30 S34 S52 S57 S83 | 7 | −22 | −15 | Yes | yes | No | No | No | + (very low) |
| Emotional statusS30 S52 | 2 | −22 | Yes | Yes | −11 | No | No | No | + (very low) |
| Exercise capacity (VO2 max, 6MWD)S1 S6 S34 S37 S49 S52 S57 S74 S83 | 9 | −22 | −15 | Yes | yes | No | No | No | + (very low) |
| FEV1S6 S22 S30 S34 S41 S42 S49 S57 S58 S71 S81 S82 S83 S86 | 14 | −12 | −15 | Yes | −11 | No | No | No | + (very low) |
| FVCS34 S57 | 2 | −12 | Yes | Yes | −11 | No | No | −112 | + (very low) |
| Gas exchange (DLco)S34 S74 | 2 | −22 | −14 | Yes | yes | No | No | No | + (very low) |
| Gas exchange (PCO2)S30 S34 | 2 | −22 | −14 | Yes | yes | No | No | No | + (very low) |
| Gas exchange (PO2)S30 S34 | 2 | −22 | −14 | Yes | yes | No | No | No | + (very low) |
| HyperinflationS34 S37 S42 S57 S58 | 5 | −22 | Yes | Yes | yes | No | No | No | ++ (low) |
| Osteoarticular conditionS30 S49 | 2 | −22 | −14 | Yes | −11 | No | −16 | No | + (very low) |
| Previous exacerbationS11 S30 S56 | 3 | −12 | −14 | Yes | yes | No | No | −17 | + (very low) |
| Quality of life/health-related quality of lifeS1 S30 S34 S49 S57 | 5 | −22 | −14 | Yes | yes | No | No | No | + (very low) |
| Self-efficacyS1 S37 | 2 | −22 | Yes | Yes | yes | No | No | −17 | + (very low) |
| Systemic inflammationS34 S81 | 2 | −22 | −15 | Yes | yes | No | No | −17 | + (very low) |
| Dietary interventionS16 S84 | 2 | Yes | Yes | Yes | −11 | No | No | −112 | ++ (low) |
| Exercise trainingS3 S4 S7 S12 S15 S17 S18 S20 S21 S27 S28 S46 S53 S60 S61 S64 S65 S66 S69 S70 S79 | 21 | Yes | −18 | Yes | −11 | No | No | No | ++ (low) |
| Long-acting β2 agonist/corticosteroidsS30 S34 S38 | 3 | −22 | −18 | Yes | −11 | No | −16 | No | + (very low) |
| Long-term oxygen therapyS30 S34 S54 S63 S72 S75 | 6 | Yes | Yes | Yes | −11 | No | No | −110,11 | ++ (low) |
| Physical activity adviceS19 S51 S85 | 3 | Yes | −18 | Yes | −11 | No | −19 | No | + (very low) |
| BalanceS2 S62 | 2 | −12 | −18 | Yes | −11 | No | No | −112,13 | + (very low) |
| Bone mineral densityS9 S67 | 2 | −22 | −18 | Yes | −11 | No | No | −113 | + (very low) |
| DyspnoeaS33 S44 | 2 | −12 | Yes | Yes | Yes | No | No | −113 | ++ (low) |
| ExacerbationsS5 S14 S29 S31 S32 S35 S50 S56 | 8 | Yes | Yes | Yes | Yes | No | No | −113 | +++ (moderate) |
| Exercise capacity (6MWD)S13 S23 S33 S76 | 4 | −12 | Yes | Yes | Yes | No | No | −113 | ++ (low) |
| FEV1S33 S44 | 2 | −22 | Yes | Yes | Yes | No | No | −113 | + (very low) |
| MortalityS24 S26 S31 S32 S35 S55 S80 | 7 | Yes | Yes | Yes | Yes | No | No | −113 | +++ (moderate) |
| Quality of life/health-related quality of lifeS24 S25 S40 S44 | 4 | Yes | Yes | Yes | −11 | No | No | −113 | ++ (low) |
Interpretation of the categories of the quality of evidence: + (very low), there is a little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect; ++ (low), the confidence in the effect estimated is limited, the true effect may be substantially different from the estimate of the effect; +++ (moderate), there is a moderate confidence that the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; and ++++ (high), there is high confidence that the true effect lies close to that of the estimate of the effect.
Reasons for upgrading or downgrading:
1Inconsistent effects (eg, different direction of effects) across and/or within studies with statistically significant and/or non-significant results.
2Direction could not be established because the majority (–1) or all (–2) studies were cross-sectional studies.
3The majority of studies included some sources of highly selected population (patients candidates for lung volume reduction surgery, patients with very severe COPD or patients included in a rehabilitation programme).
4No control for confounding.
5Only some studies had some control for confounding.
6Determinant was self-reported in most/all studies.
7The measures of exposure were so different that results could not be compared.
8The majority of studies without control group.
995% CIs too wide to interpret the effect estimates.
10Measures of physical activity too different to allow comparison of results across studies.
11Potential confounding by indication.
12Studies with small to moderate sample size.
13Too few measures of physical activity (eg, only indirect and no activity monitor) to judge association with physical activity.
DLCO, Diffusing Lung capacity for carbon monoxide; FEV1, Forced Expiratory Volume in the first second; FVC, Forced Vital Capacity; PCO2, Partial Pressure of Carbon Dioxide; PO2, Partial Pressure of Oxygen; VO2 max, Maximal Oxygen Uptake; 6MWD, 6 min walk distance.
Figure 2Graphical illustration of the individual study effects of physical activity on reduced risk of exacerbations. Pitta 2006 was excluded from the graph because it did not provide a risk ratio.
Figure 3Graphical illustration of the individual study effects of physical activity on reduced risk of mortality.
Figure 4Conceptual model of physical activity in patients with COPD. Grading was done separately for each individual determinant/outcome (table 2). Variables of the same category sharing the same confidence rating are grouped together in this figure for clarity. Socio-demographic, lifestyle and environment, and some clinical variables (FEV1, body mass index, emotional status and comorbidities) do not show consistent effects on physical activity. The association between other clinical and functional determinants and physical activity such as hyperinflation, exercise capacity, dyspnoea, previous exacerbations, gas exchange, systemic inflammation, quality of life and self-efficacy is consistent across studies, but lacking directionality because mostly it is based on cross-sectional studies. Studies on pharmacological and non-pharmacological treatments as determinants of physical activity are all longitudinal and thus, by design, provided a basis for a clear direction of the associations. But the results are inconsistent with some treatments showing an increase in physical activity and some showing no effect. Regarding the outcomes, only COPD exacerbation and mortality show consistent effects with clear directionality and based on moderate quality evidence.